Substance / Medication

Tenofovir alafenamide fumarate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Chronic type B viral hepatitis

AIDS

Type B viral hepatitis

Human immunodeficiency virus infection

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

198 trials linked to this intervention

198

Total Trials

Recruiting

With Results

Recent Trials

Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection

NCT00004850Completed805 enrolled

Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

NCT00106964Phase 4Completed371 enrolled

Long-Term Lamivudine Therapy for Chronic Hepatitis B

NCT00120354Phase 4Completed50 enrolled

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

NCT00127959Phase 4Completed24 enrolled

Immunologic Memory (Supp. of ATN 024)

NCT00142753Phase 4Completed95 enrolled

View all 198 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Effectiveness and Safety of Tenofovir Alafenamide Fumarate in the Prevention of Perinatal Hepatitis B Transmission: A Meta-Analysis.

Huang Ji, Cheng Cong, Li Kangxin et al. · Dig Dis Sci · 2024

PMID: 38341392Meta-Analysis

Tenofovir Alafenamide Fumarate Reduces Virological Replication in HBeAg-Negative Patients With Normal Alanine Aminotransferase: A 48-Week Randomised Controlled Trial.

Luo Qiumin, Xu Wenxiong, Zhang Yeqiong et al. · J Viral Hepat · 2026

PMID: 41608776RCT

Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV.

Moore Amelia E B, Burns James E, Sally Deirdre et al. · AIDS · 2024

PMID: 38061030RCTFull text (PMC)

Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers.

Bevers Lisanne A H, Kamphuis Anne E M, van der Wekken-Pas L C Wendy et al. · Clin Pharmacokinet · 2024

PMID: 38573477RCTFull text (PMC)

Effect of Tenofovir Alafenamide Fumarate on the outcomes of hospitalized COVID-19 patients: a prospective, block-balanced, open-label, randomized controlled trial.

Yazdan Pouri Nazanin, Shokati Eshkiki Zahra, Talebi Afshin et al. · BMC Pharmacol Toxicol · 2024

PMID: 39420385RCTFull text (PMC)

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.

Hoffman Risa M, Brummel Sean, Ziemba Lauren et al. · Clin Infect Dis · 2024

PMID: 38180851RCTFull text (PMC)

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.

Waalewijn Hylke, Szubert Alexander J, Wasmann Roeland E et al. · Clin Infect Dis · 2023

PMID: 37315296RCTFull text (PMC)

INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial.

Naidoo Anushka, Dooley Kelly E, Naidoo Kogieleum et al. · BMJ Open · 2022

PMID: 36356989RCTFull text (PMC)

Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load.

Li Baijun, Liu Zhaozhe, Liu Xing et al. · Hepatol Int · 2021

PMID: 34312798RCT

Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort.

Ciccullo Arturo, Baldin Gianmaria, Cervo Adriana et al. · J Antimicrob Chemother · 2025

PMID: 39478330Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Tenofovir alafenamide fumarate (substance)
SNOMED CT: 734973002
UMLS CUI: C4058841

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

198

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.